SlideShare a Scribd company logo
1 of 38
Antibiotic Dosing During Renal Failure February 1, 2010 Sarah Nelson, Pharm.D. Critical Care Pharmacy Resident
Objectives ,[object Object],[object Object],[object Object],[object Object]
Kidney Disease ,[object Object],[object Object],[object Object],Wargo et al. Comparison of the Modification of Diet in Renal Disease and Cockroft-Gault  Equations for Antimicrobial Dosage Adjustments.  The Annals of Pharmacotherapy . 2006;40:1248-1253
Importance of Renal Function ,[object Object],[object Object],[object Object],[object Object],[object Object],Livornese et al. Use of antibacterial agents in renal failure. Infect Dis Clin N Am. 2004;18:551-579
Importance of Renal Function ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Renal Excretion http://www.unckidneycenter.org/images/glomerulus.jpg
Risk Factors/Markers of Renal Impairment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Calculating GFR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Wargo et al. Comparison of the Modification of Diet in Renal Disease and Cockroft-Gault  Equations for Antimicrobial Dosage Adjustments.  The Annals of Pharmacotherapy . 2006;40:1248-1253
Calculating GFR ,[object Object],[object Object],[object Object],[object Object],[object Object],Moranville, M et al. Implications of using modification of diet in renal disease versus Cockroft-Gault  equations for renal dosing adjustments.  Am J Health-Syst Pharm.  2009;66:154-161
MDRD ,[object Object],[object Object],[object Object],[object Object],[object Object],Moranville, M et al. Implications of using modification of diet in renal disease versus Cockroft-Gault  equations for renal dosing adjustments.  Am J Health-Syst Pharm.  2009;66:154-161
MDRD ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Golik et al. Comparison of Dosing Recommendations for Antimicrobial Drugs Based on Two Methods for Assessing  Kidney Function: Cockroft-Gault and Modification of Diet in Renal Disease.  Pharmacotherapy.  2008;28(9):1125-1132
Cockroft-Gault ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Moranville, M et al. Implications of using modification of diet in renal disease versus Cockroft-Gault  equations for renal dosing adjustments.  Am J Health-Syst Pharm.  2009;66:154-161
Cockroft-Gault ,[object Object],[object Object],[object Object],[object Object],[object Object],Golik et al. Comparison of Dosing Recommendations for Antimicrobial Drugs Based on Two Methods for Assessing  Kidney Function: Cockroft-Gault and Modification of Diet in Renal Disease.  Pharmacotherapy.  2008;28(9):1125-1132
Weight Calculations ,[object Object],[object Object],[object Object]
Cockroft-Gault ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
TIME OUT!! ,[object Object],[object Object],[object Object],[object Object],[object Object],SCr Weight Height 1.9 mg/dL 57 kg 5'3"
Pause for the Cause! ,[object Object],[object Object],[object Object],[object Object],[object Object],SCr Weight Height 2.85 mg/dL 86 kg 5‘10"
Which should I use? ,[object Object],[object Object],[object Object],[object Object],Wargo et al. Comparison of the Modification of Diet in Renal Disease and Cockroft-Gault  Equations for Antimicrobial Dosage Adjustments.  The Annals of Pharmacotherapy . 2006;40:1248-1253
Beware! ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dosing in Renal Failure ,[object Object],[object Object],[object Object],[object Object]
Factors to Consider when Adjusting Dose ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Stages of Kidney Disease Adapted from the National Kidney Foundation Stage Description GFR (mL/min/1.73 m 2 ) 1 Kidney damage with normal GFR ≥ 90 2 Kidney damage with mild ↓ in GFR 60-89 3 Moderate ↓ GFR 30-59 4 Severe ↓ GFR 15-29 5 Kidney Failure <15 (or dialysis)
Dialysis ,[object Object],[object Object],[object Object],[object Object],[object Object],Rowland, Malcolm (1995).  Clinical Pharmacokinetics: Concepts and Applications . 3 rd  Ed. USA: Lippincott, Williams, and Wilkins. 448-453.
Dialysis ,[object Object],[object Object],[object Object],[object Object],[object Object],Rowland, Malcolm (1995).  Clinical Pharmacokinetics: Concepts and Applications . 3 rd  Ed. USA: Lippincott, Williams, and Wilkins. 448-453.
Continuous Dialysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Trotman et al. Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous  Renal Replacement Therapy.  CID . 2005;41:1159-1166
Adjusting Antimicrobials During Dialysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
References ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Example #1: Fluconazole ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Example #1: Fluconazole ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Example #1: Fluconazole ,[object Object],[object Object]
Example #2: Pip/Tazo ,[object Object],[object Object],1/19 1/20 1/22 1/23 Scr 0.9mg/dL 1.1mg/dL 1.24mg/dL 1.45mg/dL Weight Height UO 87 kg 5’4” 44 mL/hour
Example #2: Pip/Tazo ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Example #2: Pip/Tazo ,[object Object],[object Object],[object Object]
Example #3: Levofloxacin ,[object Object],[object Object],[object Object],[object Object],[object Object]
Example #3: Levofloxacin ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Example #3: Levofloxacin
Example #3: Levofloxacin ,[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Imeglimin a new class a new approach for diabetes management
Imeglimin a new class a new approach for diabetes management Imeglimin a new class a new approach for diabetes management
Imeglimin a new class a new approach for diabetes management yara eid
 
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:Naina Mohamed, PhD
 
Presentation Tamsulosin
Presentation TamsulosinPresentation Tamsulosin
Presentation TamsulosinAkshay Roy
 
Estimation of glomerular filtration rate
Estimation of glomerular filtration rateEstimation of glomerular filtration rate
Estimation of glomerular filtration rateArun Raj
 
Antiplatelets and anticoagulants
Antiplatelets and anticoagulantsAntiplatelets and anticoagulants
Antiplatelets and anticoagulantsEdson Mutandwa
 
Sodium glucose co transporter( SGLT2) Inhibitors
Sodium glucose co transporter( SGLT2) Inhibitors Sodium glucose co transporter( SGLT2) Inhibitors
Sodium glucose co transporter( SGLT2) Inhibitors Philip Vaidyan
 
IMEglimin .pptx
IMEglimin .pptxIMEglimin .pptx
IMEglimin .pptxHarsh shaH
 
Beta-blockers in cardiovascular diseases
Beta-blockers in cardiovascular diseasesBeta-blockers in cardiovascular diseases
Beta-blockers in cardiovascular diseasesKunal Mahajan
 
ARNI : Dr. Akif Baig
ARNI : Dr. Akif BaigARNI : Dr. Akif Baig
ARNI : Dr. Akif Baigakifab93
 
Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8nik_sat
 

What's hot (20)

Oral hypoglycaemic drugs
Oral hypoglycaemic drugsOral hypoglycaemic drugs
Oral hypoglycaemic drugs
 
ARB in the management of Hypertension
ARB in the management of HypertensionARB in the management of Hypertension
ARB in the management of Hypertension
 
Imeglimin a new class a new approach for diabetes management
Imeglimin a new class a new approach for diabetes management Imeglimin a new class a new approach for diabetes management
Imeglimin a new class a new approach for diabetes management
 
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
SGLT2 Inhibitors (Gliflozins): A New Class of Drugs to treat Type 2 Diabetes:
 
Presentation Tamsulosin
Presentation TamsulosinPresentation Tamsulosin
Presentation Tamsulosin
 
Estimation of glomerular filtration rate
Estimation of glomerular filtration rateEstimation of glomerular filtration rate
Estimation of glomerular filtration rate
 
Diabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 UpdateDiabetic Kidney Disease 2022 Update
Diabetic Kidney Disease 2022 Update
 
Antiplatelets and anticoagulants
Antiplatelets and anticoagulantsAntiplatelets and anticoagulants
Antiplatelets and anticoagulants
 
Inpatient Management of Hyperglycemia
Inpatient Management of HyperglycemiaInpatient Management of Hyperglycemia
Inpatient Management of Hyperglycemia
 
SGLT-2
SGLT-2 SGLT-2
SGLT-2
 
Rosuvastatin
RosuvastatinRosuvastatin
Rosuvastatin
 
Telmisartan
TelmisartanTelmisartan
Telmisartan
 
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada SelimEmpagliflozin glycemic control and beyond-Dr Shahjada Selim
Empagliflozin glycemic control and beyond-Dr Shahjada Selim
 
Sodium glucose co transporter( SGLT2) Inhibitors
Sodium glucose co transporter( SGLT2) Inhibitors Sodium glucose co transporter( SGLT2) Inhibitors
Sodium glucose co transporter( SGLT2) Inhibitors
 
Dpp – 4 inhibitors
Dpp – 4 inhibitorsDpp – 4 inhibitors
Dpp – 4 inhibitors
 
IMEglimin .pptx
IMEglimin .pptxIMEglimin .pptx
IMEglimin .pptx
 
Beta-blockers in cardiovascular diseases
Beta-blockers in cardiovascular diseasesBeta-blockers in cardiovascular diseases
Beta-blockers in cardiovascular diseases
 
Trimetazidine
TrimetazidineTrimetazidine
Trimetazidine
 
ARNI : Dr. Akif Baig
ARNI : Dr. Akif BaigARNI : Dr. Akif Baig
ARNI : Dr. Akif Baig
 
Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8Hypertension Guidelines JNC 8
Hypertension Guidelines JNC 8
 

Viewers also liked

Part 2 - Aminoglycoside Vancomycin dosing
Part 2 - Aminoglycoside  Vancomycin dosingPart 2 - Aminoglycoside  Vancomycin dosing
Part 2 - Aminoglycoside Vancomycin dosingJeff Tollison
 
Dose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failureDose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failurePallavi Kurra
 
Drug use in hepatic and renal impairment
Drug use in hepatic and renal impairmentDrug use in hepatic and renal impairment
Drug use in hepatic and renal impairmentAkshil Mehta
 
Vancomycin hydrochloride
Vancomycin hydrochlorideVancomycin hydrochloride
Vancomycin hydrochlorideChris W
 
Management Of The Morbidly Obese
Management Of The Morbidly ObeseManagement Of The Morbidly Obese
Management Of The Morbidly Obesenels1937
 
Brief review of renal failure with chemotherapeutic agents
Brief review of renal failure with chemotherapeutic agentsBrief review of renal failure with chemotherapeutic agents
Brief review of renal failure with chemotherapeutic agentsKasarla Dr Ramesh
 
Drug profiles of Vancomycin, Prednisone and Salbutamol
Drug profiles of Vancomycin, Prednisone and SalbutamolDrug profiles of Vancomycin, Prednisone and Salbutamol
Drug profiles of Vancomycin, Prednisone and SalbutamolKomal Haleem
 
Preventive and therapeutic strategies in critically ill patients with highly...
 Preventive and therapeutic strategies in critically ill patients with highly... Preventive and therapeutic strategies in critically ill patients with highly...
Preventive and therapeutic strategies in critically ill patients with highly...Sergio Paul Silva Marin
 
Van de graff ppt
Van de graff pptVan de graff ppt
Van de graff pptKinjal Jain
 
Drugs and the kidney
Drugs and the kidneyDrugs and the kidney
Drugs and the kidneyraj kumar
 

Viewers also liked (20)

Part 2 - Aminoglycoside Vancomycin dosing
Part 2 - Aminoglycoside  Vancomycin dosingPart 2 - Aminoglycoside  Vancomycin dosing
Part 2 - Aminoglycoside Vancomycin dosing
 
Dose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failureDose Adjustment in renal and hepatic failure
Dose Adjustment in renal and hepatic failure
 
Drug use in hepatic and renal impairment
Drug use in hepatic and renal impairmentDrug use in hepatic and renal impairment
Drug use in hepatic and renal impairment
 
Dosing of drugs in liver failure
Dosing of drugs in liver failureDosing of drugs in liver failure
Dosing of drugs in liver failure
 
Vancomycin hydrochloride
Vancomycin hydrochlorideVancomycin hydrochloride
Vancomycin hydrochloride
 
Drug dosing
Drug dosingDrug dosing
Drug dosing
 
Chronic renal failure, surgical management
Chronic renal failure, surgical managementChronic renal failure, surgical management
Chronic renal failure, surgical management
 
Management Of The Morbidly Obese
Management Of The Morbidly ObeseManagement Of The Morbidly Obese
Management Of The Morbidly Obese
 
Brief review of renal failure with chemotherapeutic agents
Brief review of renal failure with chemotherapeutic agentsBrief review of renal failure with chemotherapeutic agents
Brief review of renal failure with chemotherapeutic agents
 
Vancomycin
VancomycinVancomycin
Vancomycin
 
Drug profiles of Vancomycin, Prednisone and Salbutamol
Drug profiles of Vancomycin, Prednisone and SalbutamolDrug profiles of Vancomycin, Prednisone and Salbutamol
Drug profiles of Vancomycin, Prednisone and Salbutamol
 
Preventive and therapeutic strategies in critically ill patients with highly...
 Preventive and therapeutic strategies in critically ill patients with highly... Preventive and therapeutic strategies in critically ill patients with highly...
Preventive and therapeutic strategies in critically ill patients with highly...
 
Antimicrobials general I
Antimicrobials general IAntimicrobials general I
Antimicrobials general I
 
Van de graff ppt
Van de graff pptVan de graff ppt
Van de graff ppt
 
Antibiotics
AntibioticsAntibiotics
Antibiotics
 
M1 accelerators
M1 acceleratorsM1 accelerators
M1 accelerators
 
Drugs and the kidney
Drugs and the kidneyDrugs and the kidney
Drugs and the kidney
 
Accelerator
AcceleratorAccelerator
Accelerator
 
kamal project ppt
kamal project pptkamal project ppt
kamal project ppt
 
Van de graaff
Van de graaffVan de graaff
Van de graaff
 

Similar to Antibiotic Dosing During Renal Failure

Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?PASaskatchewan
 
Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...Greenberg, Eric
 
Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease.
Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease. Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease.
Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease. Kevin John
 
38 use of drugs in children with impaired renal function
38 use of drugs in children with impaired renal function38 use of drugs in children with impaired renal function
38 use of drugs in children with impaired renal functionDang Thanh Tuan
 
Dosage regimen in renal failure ( Neha Mayekar).pptx
Dosage regimen in renal failure ( Neha Mayekar).pptxDosage regimen in renal failure ( Neha Mayekar).pptx
Dosage regimen in renal failure ( Neha Mayekar).pptxSaishDalvi
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokineticsDang Thanh Tuan
 
Initiation And Incremental Dialysis
Initiation And Incremental DialysisInitiation And Incremental Dialysis
Initiation And Incremental Dialysisedwinchowyw
 
Newer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicityNewer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicitykdj200
 
Transporters and Their Role in Drug Interactions
Transporters and Their Role in Drug InteractionsTransporters and Their Role in Drug Interactions
Transporters and Their Role in Drug Interactionsshabeel pn
 
Renal-prescribing-NMP-forum-July-2019.pdf
Renal-prescribing-NMP-forum-July-2019.pdfRenal-prescribing-NMP-forum-July-2019.pdf
Renal-prescribing-NMP-forum-July-2019.pdfOctavioGamez1
 
17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf foudaFarragBahbah
 
Pharmacokinetics in the Critically Ill
Pharmacokinetics in the Critically IllPharmacokinetics in the Critically Ill
Pharmacokinetics in the Critically IllSMACC Conference
 
HepaticDosageAdjustment.pdf
HepaticDosageAdjustment.pdfHepaticDosageAdjustment.pdf
HepaticDosageAdjustment.pdfHelena949653
 
SLE: present guidelines and consensus
SLE: present guidelines and consensusSLE: present guidelines and consensus
SLE: present guidelines and consensusVishal Golay
 

Similar to Antibiotic Dosing During Renal Failure (20)

Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?Creatinine clearance: When Does It Matter?
Creatinine clearance: When Does It Matter?
 
Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...Drug dosage adjustment using renal estimation equations. A review of the lite...
Drug dosage adjustment using renal estimation equations. A review of the lite...
 
E gfr for web
E gfr for webE gfr for web
E gfr for web
 
Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease.
Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease. Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease.
Dose Adjustment in Acute Renal Failure and Chronic Kidney Disease.
 
Journal club: Is Early Dialysis Better?
Journal club: Is Early Dialysis Better?Journal club: Is Early Dialysis Better?
Journal club: Is Early Dialysis Better?
 
38 use of drugs in children with impaired renal function
38 use of drugs in children with impaired renal function38 use of drugs in children with impaired renal function
38 use of drugs in children with impaired renal function
 
Dosage regimen in renal failure ( Neha Mayekar).pptx
Dosage regimen in renal failure ( Neha Mayekar).pptxDosage regimen in renal failure ( Neha Mayekar).pptx
Dosage regimen in renal failure ( Neha Mayekar).pptx
 
35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics35 effects of renal disease on pharmacokinetics
35 effects of renal disease on pharmacokinetics
 
Initiation And Incremental Dialysis
Initiation And Incremental DialysisInitiation And Incremental Dialysis
Initiation And Incremental Dialysis
 
Voclosporin journal club
Voclosporin journal clubVoclosporin journal club
Voclosporin journal club
 
Newer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicityNewer Chemotherapy agents and renal toxicity
Newer Chemotherapy agents and renal toxicity
 
Transporters and Their Role in Drug Interactions
Transporters and Their Role in Drug InteractionsTransporters and Their Role in Drug Interactions
Transporters and Their Role in Drug Interactions
 
Renal-prescribing-NMP-forum-July-2019.pdf
Renal-prescribing-NMP-forum-July-2019.pdfRenal-prescribing-NMP-forum-July-2019.pdf
Renal-prescribing-NMP-forum-July-2019.pdf
 
17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda17 february lupus nephritis prof ashraf fouda
17 february lupus nephritis prof ashraf fouda
 
Pharmacokinetics in the Critically Ill
Pharmacokinetics in the Critically IllPharmacokinetics in the Critically Ill
Pharmacokinetics in the Critically Ill
 
Ckd
CkdCkd
Ckd
 
Euvas trials
Euvas trialsEuvas trials
Euvas trials
 
HepaticDosageAdjustment.pdf
HepaticDosageAdjustment.pdfHepaticDosageAdjustment.pdf
HepaticDosageAdjustment.pdf
 
SLE: present guidelines and consensus
SLE: present guidelines and consensusSLE: present guidelines and consensus
SLE: present guidelines and consensus
 
2010 uptodate adequacy dp
2010 uptodate adequacy dp2010 uptodate adequacy dp
2010 uptodate adequacy dp
 

Antibiotic Dosing During Renal Failure